TD Cowen Raises TMO Price Target to $760

TD Cowen has reaffirmed its Buy rating on Thermo Fisher Scientific Inc. (NYSE: TMO) with a new price target of $760, raised from $675, on October 13, 2026.

TD Cowen's Call on Thermo Fisher Scientific

TD Cowen maintained its Buy rating on Thermo Fisher, increasing the price target to $760. This represents a significant uplift from the prior target of $675. The stock was recently trading at $685.18, which puts it about 9.8% below the new target price.

Other Institutional Activity in Thermo Fisher Scientific

Several other funds have made movements in Thermo Fisher shares. Blackrock Inc. grew its holdings by 492,913 shares, ending with about 30.9 million shares valued at approximately $21.3 billion. Meanwhile, FMR, LLC added 3,308,292 shares, bringing its total to about 14.1 million shares worth around $9.7 billion. State Street Corporation increased its stake by 93,700 shares, totaling about 16.8 million shares valued at approximately $11.6 billion.

Thermo Fisher Scientific Inc. Stock Down 1.6%

Thermo Fisher shares are currently trading at $685.18, which is below the new target of $760. This gap might indicate potential for growth if the stock can reach the analyst's target. The company has shown strong performance with a revenue growth of 10.5% year-over-year, suggesting solid demand for its products.

Recent Earnings

Thermo Fisher reported trailing twelve-month revenue of about $46.3 billion and earnings per share of $18.57. The company has a net margin of 15.0% and a return on equity of 13.5%. Investors will be looking closely at the upcoming earnings report on October 21, 2026, to see how these trends continue.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Recent insider activity includes CEO Marc N. Casper, who sold 20,000 shares on August 21, 2026, worth about $12.6 million. Additionally, he sold another 275 shares on August 24, valued at approximately $172,439. Officer Lisa P Britt sold 11,440 shares on August 19, worth around $7.0 million, and President Gianluca Pettiti sold 4,133 shares on August 31, valued at approximately $2.5 million. These transactions occurred before the recent analyst updates.

Analysts Set New Price Targets

On October 13, 2026, Morgan Stanley maintained its Overweight rating on Thermo Fisher with a price target of $730, while TD Cowen reiterated its Buy rating with a new target of $760. Earlier, Barclays also maintained its Overweight rating with a target of $750. The consensus from analysts shows a strong outlook for the stock with several positive ratings.

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides a wide range of life sciences solutions, analytical instruments, and laboratory products. It operates in four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company is headquartered in Waltham, MA, and employs about 125,000 people.

Bottom Line

Investors should watch for Thermo Fisher's upcoming earnings report on October 21, 2026. With a current share price below the new analyst target, there could be potential for movement if the company continues to show strong performance. Keep an eye on further analyst updates as well, especially from firms like TD Cowen and Morgan Stanley.